FIELD: medicine.
SUBSTANCE: application of the composition containing an indolyl-acetic acid (IAA) in quality of an active ingredient is offered, which activates hypothalamus in order to raise level of a hormone releasing the hormone of growth (GHRH), in blood serum which in turn leads to rising of secretion of the hormone of growth (GH) and to the subsequent rising of level of the insulin-like factor of growth 1 (IGF-1) in blood serum, for preparation of a therapeutic composition for treatment at: people - a chronic fatigue syndrome, diabetes of 2nd type, for immune therapy or for stimulating restoration after physical trainings or rising of immunity at animals. The composition can be produced in the form of the accessory food substance. Improvement of condition of pigs is shown with; a staphylococcal infection, good gain in weight and muscular mass, augmentation of IGF-1 concentration. It is shown an ergogenic effect of IAA at sportsmen.
EFFECT: improvement of condition of pigs with; staphylococcal infection, good gain in weight and muscular mass, augmentation of IGF-1 concentration.
5 cl, 8 dwg, 11 ex, 8 tbl
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL OR DIETETIC COMPOSITION FOR REDUCING MAMMAL BLOOD IGF-I LEVEL AND METHOD FOR REDUCING IGF-I LEVEL | 2000 |
|
RU2242220C2 |
PHARMACEUTICAL COMPOSITION FOR GROWTH HORMONE DEFICIENCY THERAPY COMPRISING FUSED hGH PROTEIN | 2017 |
|
RU2748402C2 |
HUMANIZED ANTIBODY AGAINST IGF-1 RECEPTOR | 2019 |
|
RU2784079C1 |
PEPTIDE ANALOGUE COMPOUNDS OF GROWTH HORMONE SECRETION STIMULANTS AND PREPARATIONS CONTAINING SAID COMPOUNDS | 2007 |
|
RU2416618C2 |
TREATMENT OF NEUROPATHY WITH DNA STRUCTURES ENCODING IGF-1 AND DNA STRUCTURES ENCODING HGF | 2019 |
|
RU2781980C2 |
ANTIBODY AGAINST IGF-I RECEPTOR | 2018 |
|
RU2785305C2 |
ANALOGUES OF INSULIN-LIKE GROWTH FACTOR-1 (IGF-1), CONTAINING AMINO ACID SUBSTITUTION IN POSITION 59 | 2010 |
|
RU2511577C2 |
HYBRID PROTEIN IGF-1-LONG FOR TREATING STROKE, NUCLEIC ACID, VECTOR, CELL, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT | 2018 |
|
RU2711111C1 |
USE OF LONG-ACTING GLP-1 PEPTIDES | 2013 |
|
RU2657573C2 |
TREATMENT METHOD | 2006 |
|
RU2397778C2 |
Authors
Dates
2009-07-20—Published
2003-10-03—Filed